Shares of Intellia Therapeutics (NASDAQ:NTLA) have been assigned a consensus rating of “Buy” from the thirteen analysts that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $38.00.
Several equities research analysts have issued reports on the company. Barclays increased their price target on Intellia Therapeutics from $33.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, March 7th. JMP Securities assumed coverage on Intellia Therapeutics in a report on Thursday, March 8th. They set an “outperform” rating for the company. Leerink Swann reiterated an “outperform” rating on shares of Intellia Therapeutics in a report on Wednesday, March 14th. Chardan Capital upgraded Intellia Therapeutics from a “neutral” rating to a “buy” rating in a report on Tuesday, May 15th. Finally, Wedbush reiterated an “outperform” rating and set a $36.00 price objective on shares of Intellia Therapeutics in a report on Friday.
In related news, Director Jean Francois Formela sold 6,686 shares of the stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $25.04, for a total transaction of $167,417.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John M. Leonard sold 8,400 shares of the stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $24.00, for a total value of $201,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,331 shares of company stock valued at $1,305,796. 3.20% of the stock is owned by corporate insiders.
Hedge funds have recently bought and sold shares of the business. MetLife Investment Advisors LLC bought a new position in Intellia Therapeutics in the fourth quarter valued at approximately $146,000. Commonwealth Equity Services LLC bought a new position in Intellia Therapeutics in the first quarter valued at approximately $204,000. Cubist Systematic Strategies LLC bought a new position in Intellia Therapeutics in the first quarter valued at approximately $252,000. Fox Run Management L.L.C. bought a new position in Intellia Therapeutics in the fourth quarter valued at approximately $230,000. Finally, Slow Capital Inc. acquired a new stake in shares of Intellia Therapeutics in the fourth quarter valued at approximately $294,000. Hedge funds and other institutional investors own 60.77% of the company’s stock.
Shares of Intellia Therapeutics traded up $0.27, hitting $24.61, during trading hours on Thursday, Marketbeat Ratings reports. The company’s stock had a trading volume of 27,743 shares, compared to its average volume of 887,351. Intellia Therapeutics has a 12 month low of $11.15 and a 12 month high of $35.99. The company has a market capitalization of $1.07 billion, a P/E ratio of -13.05 and a beta of 2.85.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Tuesday, May 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.07. Intellia Therapeutics had a negative return on equity of 31.80% and a negative net margin of 278.64%. The company had revenue of $7.47 million during the quarter, compared to the consensus estimate of $6.14 million. equities research analysts expect that Intellia Therapeutics will post -2 EPS for the current fiscal year.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.